We have located links that may give you full text access.
Critical Dependence on Area in Relationship between ARMS2/HTRA1 Genotype and Faster Geographic Atrophy Enlargement: AREDS2 Report 33.
Ophthalmology 2023 September 16
PURPOSE: To analyze ARMS2/HTRA1 as a risk factor for faster geographic atrophy (GA) enlargement according to (i) GA area and (ii) contiguous enlargement versus progression to multifocality.
DESIGN: Post hoc analysis of a cohort within the Age-Related Eye Disease Study 2 (AREDS2) clinical trial.
PARTICIPANTS: 546 eyes (406 participants, mean age 73.8 years) with GA.
METHODS: GA area was measured from color fundus photographs at annual visits. Mixed-model regression of square root GA area, and proportional hazards regression of progression to multifocal GA, were analyzed according to ARMS2 genotype.
MAIN OUTCOME MEASURES: (i) change in square root GA area; (ii) progression to multifocal GA.
RESULTS: GA enlargement was significantly faster in eyes with ARMS2 risk alleles (P<0.0001), at 0.224 mm/year (95% CI 0.195-0.252), 0.298 (0.271-0.324), and 0.317 (0.279-0.355), for 0-2 risk alleles, respectively. However, a significant interaction (P=0.011) was observed between genotype and baseline GA area. In eyes with very small GA area (<1.9 mm2 ), enlargement was significantly faster with ARMS2 risk alleles (P<0.0001), at 0.193 mm/year (0.162-0.225) versus 0.304 (0.280-0.329), for 0 versus 1-2 risk alleles, respectively. In eyes with moderately small (1.9-3.8 mm2 ) or medium/large (≥3.8 mm2 ) GA area, enlargement was not significantly faster with ARMS2 risk alleles (P=0.66 and P=0.70, respectively). In eyes with non-multifocal GA, enlargement was significantly faster with ARMS2 risk alleles (P=0.001), at 0.175 mm/year (0.142-0.209), 0.226 (0.193-0.259), and 0.287 (0.237-0.337), with 0-2 risk alleles, respectively. ARMS2 genotype was not significantly associated with progression to multifocal GA; the hazard ratios for 1 and 2 risk alleles, respectively, were 1.03 (0.70-1.53; P=0.87) and 1.12 (0.67-1.88; P=0.66).
CONCLUSIONS: The relationship between ARMS2/HTRA1 genotype and faster GA enlargement depends critically on GA area: risk alleles represent a strong risk factor for faster enlargement only in eyes with very small GA area. They increase the growth rate more through contiguous enlargement than progression to multifocality. ARMS2/HTRA1 genotype is more important in increasing risk of progression to GA and initial GA enlargement (contiguously) than in subsequent enlargement or progression to multifocality. These findings may explain some discrepancies between previous studies and have implications for both research and clinical practice.
DESIGN: Post hoc analysis of a cohort within the Age-Related Eye Disease Study 2 (AREDS2) clinical trial.
PARTICIPANTS: 546 eyes (406 participants, mean age 73.8 years) with GA.
METHODS: GA area was measured from color fundus photographs at annual visits. Mixed-model regression of square root GA area, and proportional hazards regression of progression to multifocal GA, were analyzed according to ARMS2 genotype.
MAIN OUTCOME MEASURES: (i) change in square root GA area; (ii) progression to multifocal GA.
RESULTS: GA enlargement was significantly faster in eyes with ARMS2 risk alleles (P<0.0001), at 0.224 mm/year (95% CI 0.195-0.252), 0.298 (0.271-0.324), and 0.317 (0.279-0.355), for 0-2 risk alleles, respectively. However, a significant interaction (P=0.011) was observed between genotype and baseline GA area. In eyes with very small GA area (<1.9 mm2 ), enlargement was significantly faster with ARMS2 risk alleles (P<0.0001), at 0.193 mm/year (0.162-0.225) versus 0.304 (0.280-0.329), for 0 versus 1-2 risk alleles, respectively. In eyes with moderately small (1.9-3.8 mm2 ) or medium/large (≥3.8 mm2 ) GA area, enlargement was not significantly faster with ARMS2 risk alleles (P=0.66 and P=0.70, respectively). In eyes with non-multifocal GA, enlargement was significantly faster with ARMS2 risk alleles (P=0.001), at 0.175 mm/year (0.142-0.209), 0.226 (0.193-0.259), and 0.287 (0.237-0.337), with 0-2 risk alleles, respectively. ARMS2 genotype was not significantly associated with progression to multifocal GA; the hazard ratios for 1 and 2 risk alleles, respectively, were 1.03 (0.70-1.53; P=0.87) and 1.12 (0.67-1.88; P=0.66).
CONCLUSIONS: The relationship between ARMS2/HTRA1 genotype and faster GA enlargement depends critically on GA area: risk alleles represent a strong risk factor for faster enlargement only in eyes with very small GA area. They increase the growth rate more through contiguous enlargement than progression to multifocality. ARMS2/HTRA1 genotype is more important in increasing risk of progression to GA and initial GA enlargement (contiguously) than in subsequent enlargement or progression to multifocality. These findings may explain some discrepancies between previous studies and have implications for both research and clinical practice.
Full text links
Trending Papers
Monitoring Macro- and Microcirculation in the Critically Ill: A Narrative Review.Avicenna Journal of Medicine 2023 July
ASA Consensus-based Guidance on Preoperative Management of Patients on Glucagon-like Peptide-1 Receptor Agonists.Anesthesiology 2023 November 21
Common postbariatric surgery emergencies for the acute care surgeon: What you need to know.Journal of Trauma and Acute Care Surgery 2023 December 2
Sodium bicarbonate Ringer's solution for hemorrhagic shock: A meta-analysis comparing crystalloid solutions.American Journal of Emergency Medicine 2023 November 6
Association between postinduction hypotension and postoperative mortality: a single-centre retrospective cohort study.Canadian Journal of Anaesthesia 2023 November 22
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app